CL2015002456A1 - Tratamiento de la deficiencia de la hormona del crecimiento pediátrica con análogos de la hormona del crecimiento humano - Google Patents

Tratamiento de la deficiencia de la hormona del crecimiento pediátrica con análogos de la hormona del crecimiento humano

Info

Publication number
CL2015002456A1
CL2015002456A1 CL2015002456A CL2015002456A CL2015002456A1 CL 2015002456 A1 CL2015002456 A1 CL 2015002456A1 CL 2015002456 A CL2015002456 A CL 2015002456A CL 2015002456 A CL2015002456 A CL 2015002456A CL 2015002456 A1 CL2015002456 A1 CL 2015002456A1
Authority
CL
Chile
Prior art keywords
growth hormone
pediatric
treatment
human
xten
Prior art date
Application number
CL2015002456A
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey L Cleland
George M Bright
Eric Humphriss
Original Assignee
Amunix Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Operating Inc filed Critical Amunix Operating Inc
Publication of CL2015002456A1 publication Critical patent/CL2015002456A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CL2015002456A 2013-03-11 2015-09-02 Tratamiento de la deficiencia de la hormona del crecimiento pediátrica con análogos de la hormona del crecimiento humano CL2015002456A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361776618P 2013-03-11 2013-03-11
US201361810786P 2013-04-11 2013-04-11
US201361835002P 2013-06-14 2013-06-14
US201361880701P 2013-09-20 2013-09-20
US201361911731P 2013-12-04 2013-12-04
US201461931987P 2014-01-27 2014-01-27
US201461948457P 2014-03-05 2014-03-05

Publications (1)

Publication Number Publication Date
CL2015002456A1 true CL2015002456A1 (es) 2016-05-27

Family

ID=51658905

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002456A CL2015002456A1 (es) 2013-03-11 2015-09-02 Tratamiento de la deficiencia de la hormona del crecimiento pediátrica con análogos de la hormona del crecimiento humano

Country Status (16)

Country Link
US (1) US20160158321A1 (enExample)
EP (1) EP2968451A4 (enExample)
JP (3) JP2016514132A (enExample)
KR (1) KR20150124955A (enExample)
CN (1) CN105209055A (enExample)
AU (1) AU2014249258A1 (enExample)
BR (1) BR112015022257A8 (enExample)
CA (1) CA2900949A1 (enExample)
CL (1) CL2015002456A1 (enExample)
EA (1) EA201591529A1 (enExample)
HK (1) HK1216617A1 (enExample)
IL (1) IL240392A0 (enExample)
MX (1) MX2015012175A (enExample)
PH (1) PH12015502063A1 (enExample)
SG (1) SG11201506732YA (enExample)
WO (1) WO2014164568A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2016109823A1 (en) * 2015-01-02 2016-07-07 Amunix Operation Inc. Treatment of pediatric growth hormone deficiency with human growth hormone analogues
WO2016124817A1 (en) 2015-02-03 2016-08-11 Beddit Oy Family sleep monitoring system
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017136583A1 (en) 2016-02-02 2017-08-10 Versartis, Inc. Growth hormone treatment adherence system
EP3416677B1 (en) 2016-02-17 2022-08-03 Genexine, Inc. Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
CN118105512A (zh) * 2016-08-30 2024-05-31 株式会社吉耐森 含有hGH融合蛋白的治疗生长激素缺乏症的药物组合物
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
KR20260039804A (ko) 2017-12-21 2026-03-20 아뮤닉스 파마슈티컬스, 인크. 유리 세그먼트 및 이것을 포함하는 결합 조성물
US11903683B2 (en) 2018-08-03 2024-02-20 Chelak Medical Solutions Inc Non-barometric determination of hemodynamic effects of cardiac arrhythmias using signals sensed by an implantable device
RU2753191C2 (ru) * 2019-09-26 2021-08-12 Федеральное государственное бюджетное учреждение науки Институт Биологии Развития им. Н.К. Кольцова Российской Академии Наук Новый рекомбинантный аналог гормона роста пролонгированного действия
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
KR102599111B1 (ko) * 2020-01-31 2023-11-07 울산대학교 산학협력단 인슐린유사성장인자-1 융합단백질 및 이의 용도
CN114258492A (zh) * 2020-07-22 2022-03-29 阿特纳赞塔里斯有限公司 一种通过使用马昔瑞林诊断儿科患者中生长激素缺乏症的筛选方法
CA3193453A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3178835T3 (da) * 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
ES2544982T3 (es) * 2009-09-02 2015-09-07 Merck Serono S.A. Método para predecir el nivel de respuesta al crecimiento
CN107320719A (zh) * 2012-06-05 2017-11-07 阿穆尼克斯运营公司 Hgh‑xten融合蛋白及其在治疗生长激素缺乏中的用途

Also Published As

Publication number Publication date
BR112015022257A2 (pt) 2017-10-10
MX2015012175A (es) 2016-01-12
IL240392A0 (en) 2015-09-24
CA2900949A1 (en) 2014-10-09
BR112015022257A8 (pt) 2018-01-23
EA201591529A1 (ru) 2016-04-29
SG11201506732YA (en) 2015-09-29
US20160158321A1 (en) 2016-06-09
JP2019056013A (ja) 2019-04-11
CN105209055A (zh) 2015-12-30
WO2014164568A1 (en) 2014-10-09
HK1216617A1 (zh) 2016-11-25
EP2968451A4 (en) 2017-01-04
JP2016514132A (ja) 2016-05-19
AU2014249258A1 (en) 2015-08-27
JP2017101074A (ja) 2017-06-08
EP2968451A1 (en) 2016-01-20
PH12015502063A1 (en) 2016-01-25
KR20150124955A (ko) 2015-11-06

Similar Documents

Publication Publication Date Title
PH12015502063A1 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
EP4003458A4 (en) Unilateral-driven drug infusion device
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
EA201991484A1 (ru) Лекарственные формы энзалутамида
MX2016008013A (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp.
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
IL285440A (en) Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
EA201391689A1 (ru) Система доставки лекарственного средства
WO2014153385A3 (en) Methods of treating metabolic disorders
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
CO2017003263A2 (es) Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2016000103A (es) Dispositivo de administracion de farmaco oral y metodos de uso del mismo.
MX377510B (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
PL3648788T3 (pl) Leczenie krwawienia z przewodu pokarmowego u pacjentów z ciężką chorobą von willebranda poprzez podanie rekombinowanego vwf
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
BR112015028890A2 (pt) derivados de piridona para o tratamento de infecções virais e outras doenças
EA201591603A1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
PT3648787T (pt) Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante